Spots Global Cancer Trial Database for A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Official Title: A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Study ID: NCT01421667
Study Description
Brief Summary: This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A). The study will also evaluate the safety and efficacy of brentuximab vedotin in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Part B) as well as further evaluate correlation of CD30 expression and response in DLBCL (Part C).
Detailed Description:
Eligibility
Minimum Age: 6 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
City of Hope, Duarte, California, United States
PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists, Oxnard, California, United States
Stanford Cancer Center, Stanford, California, United States
Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
Colorado Blood Cancer Institute, Denver, Colorado, United States
Cancer Specialists of North Florida - St. Augustine, St. Augustine, Florida, United States
Emory Winship Cancer Institute, Atlanta, Georgia, United States
Northwestern University, Chicago, Illinois, United States
University of Chicago, Chicago, Illinois, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Minnesota Oncology Hematology P.A., Minneapolis, Minnesota, United States
Washington University School of Medicine, St. Louis, Missouri, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
New York Oncology Hematology, P.C., Albany, New York, United States
NYU Clinical Cancer Center, New York, New York, United States
Columbia University Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Cleveland Clinic, The, Cleveland, Ohio, United States
Willamette Valley Cancer and Research / USOR, Eugene, Oregon, United States
Medical University of South Carolina, Charleston, South Carolina, United States
St. Francis Hospital, Greenville, South Carolina, United States
Texas Oncology - Medical City Dallas, Dallas, Texas, United States
Charles A. Sammons Cancer Center, Dallas, Texas, United States
Texas Oncology-Southwest Fort Worth, Fort Worth, Texas, United States
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
Texas Oncology - Seton Williamson, Round Rock, Texas, United States
Texas Oncology - Tyler, Tyler, Texas, United States
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
Swedish Cancer Institute Medical Oncology, Edmonds, Washington, United States
Seattle Cancer Care Alliance / University of Washington Medical Center, Seattle, Washington, United States
Northwest Cancer Specialists, P.C., Vancouver, Washington, United States
British Columbia Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
Contact Details
Name: Corinna Palanca-Wessels, MD, PhD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
